Cargando…
Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics
Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this rega...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302044/ https://www.ncbi.nlm.nih.gov/pubmed/27792016 http://dx.doi.org/10.3233/JPD-160914 |
_version_ | 1782506470022053888 |
---|---|
author | Jakubowski, Jennifer L. Labrie, Viviane |
author_facet | Jakubowski, Jennifer L. Labrie, Viviane |
author_sort | Jakubowski, Jennifer L. |
collection | PubMed |
description | Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this regard, the epigenome, which is partially dynamic, holds considerable promise for the development of molecular biomarkers for PD. Epigenetic marks are modified by both DNA sequence and environmental factors associated with PD, and such marks could serve as a unifying predictor of at-risk individuals. Epigenetic abnormalities have been detected in PD and other age-dependent neurodegenerative diseases, some of which were reported to occur early on and were reversible by PD medications. Emerging reports indicate that certain epigenetic differences observed in the PD brain are detectable in more easily accessible tissues. In this review, we examine epigenetic-based strategies for the development of PD biomarkers. Despite the complexities and challenges faced, the epigenome offers a new source of biomarkers with potential etiological relevance to PD, and may expand opportunities for personalized therapies. |
format | Online Article Text |
id | pubmed-5302044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53020442017-02-28 Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics Jakubowski, Jennifer L. Labrie, Viviane J Parkinsons Dis Review Parkinson’s disease (PD) is a prevalent neurodegenerative illness that is often diagnosed after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly needed for early diagnosis, as well as for the prediction of disease progression and treatment outcome. In this regard, the epigenome, which is partially dynamic, holds considerable promise for the development of molecular biomarkers for PD. Epigenetic marks are modified by both DNA sequence and environmental factors associated with PD, and such marks could serve as a unifying predictor of at-risk individuals. Epigenetic abnormalities have been detected in PD and other age-dependent neurodegenerative diseases, some of which were reported to occur early on and were reversible by PD medications. Emerging reports indicate that certain epigenetic differences observed in the PD brain are detectable in more easily accessible tissues. In this review, we examine epigenetic-based strategies for the development of PD biomarkers. Despite the complexities and challenges faced, the epigenome offers a new source of biomarkers with potential etiological relevance to PD, and may expand opportunities for personalized therapies. IOS Press 2017-02-07 /pmc/articles/PMC5302044/ /pubmed/27792016 http://dx.doi.org/10.3233/JPD-160914 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Jakubowski, Jennifer L. Labrie, Viviane Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title | Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title_full | Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title_fullStr | Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title_full_unstemmed | Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title_short | Epigenetic Biomarkers for Parkinson’s Disease: From Diagnostics to Therapeutics |
title_sort | epigenetic biomarkers for parkinson’s disease: from diagnostics to therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302044/ https://www.ncbi.nlm.nih.gov/pubmed/27792016 http://dx.doi.org/10.3233/JPD-160914 |
work_keys_str_mv | AT jakubowskijenniferl epigeneticbiomarkersforparkinsonsdiseasefromdiagnosticstotherapeutics AT labrieviviane epigeneticbiomarkersforparkinsonsdiseasefromdiagnosticstotherapeutics |